Rocket Pharma's Pivotal Danon Disease Trial Resumes, KRESLADI™ PDUFA Set for March 28, 2026
RCKT has more than doubled off its 52-week low of $2.19.
Summary
Rocket Pharmaceuticals reported Q4/FY2025 financial results, confirmed its cash runway into Q2 2027, and provided positive updates on its key gene therapy programs, including the resumption of the pivotal Danon disease trial and a PDUFA date for KRESLADI™.
Key Events · Product Development and Regulatory · RCKT
-
Pivotal Danon Disease Trial Resumes
The FDA lifted the clinical hold on the RP-A501 Phase 2 trial for Danon disease in August 2025, with dosing of additional patients anticipated in the first half of 2026.
-
KRESLADI™ PDUFA Date Set
The BLA resubmission for KRESLADI™ (marnetegragene autotemcel) for severe LAD-I has been accepted, with a Prescription Drug User Fee Act (PDUFA) target action date of March 28, 2026.
-
Extended Cash Runway
Rocket Pharmaceuticals reported $188.9 million in cash, cash equivalents, and investments as of December 31, 2025, which is expected to fund operations into the second quarter of 2027.
-
Reduced Operating Expenses
Research and development expenses decreased by $29.2 million and general and administrative expenses decreased by $15.5 million for the twelve months ended December 31, 2025, reflecting disciplined resource allocation and organizational realignment.
Analysis · RCKT · Life Sciences
This filing provides critical updates for Rocket Pharmaceuticals, addressing previous concerns and highlighting significant progress in its pipeline. The resumption of the pivotal Phase 2 trial for RP-A501 in Danon disease, following the lifting of a clinical hold, de-risks a key program. Additionally, the March 28, 2026 PDUFA date for KRESLADI™ creates a near-term catalyst for potential approval and a Priority Review Voucher. The reported cash position and extended operational runway into Q2 2027 provide financial stability, reflecting the impact of recent cost-cutting measures. Investors should monitor the upcoming PDUFA decision and further progress in the Danon disease trial.
At the time of this filing, RCKT was trading at $4.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $490.2M. The 52-week trading range was $2.19 to $9.84. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.